[9F8-9F8];[10A3-10A3];
A set of ~800 largely isogenic deficiency stocks created by FLP-induced recombination between FRT-carrying transgenic insertions; molecularly defined deletion endpoints correspond to initial location of the progenitor insertions. Designed to fill gaps in deletion coverage and breakpoint placement; also used to replace older available deficiencies that have not been molecularly mapped.
9F8;10A3
Breakpoint based on progenitor insertion release 3 sequence coordinate X:10834192 , per R. Hoskins (Gene Disruption Project) personal communication, mapped forward to release 5.
Breakpoint from FlyBase's release 5 sequence location of progenitor insertion.
The presence of P+PBac{XP5.RB3}BSC572 was verified using the PCR methods and primers described in FBrf0175003, with the substitution of the primer 5'-CCAATGCGTTTATTTCAGGTCACG-3' for the RB3' plus or RB3' minus primer in the Hybrid PCR protocol in the Supplementary Methods.
Exelixis, Inc. determined the insertion site of the progenitor insertion PBac{RB}e04308 to be Release 3 genomic coordinate 10834026 on the X chromosome. The Gene Disruption project determined the insertion site of the progenitor insertion PBac{RB}e04308 to be Release 3 genomic coordinate 10834192 on the X chromosome. This corresponds to 10A4 on the Release 3 and Release 5 genome maps. The predicted position of P{XP}d09152 on the Release 5 map is 9F8. Consequently, the cytological breakpoints of Df(1)BSC572 are predicted to be 9F8;10A4.